OakChart

Alvotech

ALVOHealthcare·Drug Manufacturers - Specialty & Generic·Luxembourg·Small·NASD·Nov 11 • 10:01 AM ET

4.95+0.07 (1.33%)
2026-11-11 16:02 CET
Market cap
1,905.31 USD m
Revenue, TTM
491.95 USD m
Net income, TTM
-179.59 USD m
Free cash flow, TTM
-261.38 USD m
EPS diluted, TTM
-0.56
P/E
-
Compare

Price

ALVO against its 20, 50 and 200-day averages
2050200missearnings
3.004.005.006.002.7M5.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALVOclose 4.9520-day 4.8250-day 5.27200-day 4.194.95

37.6% under 7.92 on 30 Oct 2025. Last 15 sessions, 13.4% high to low

Profile

ALVO
52-week range, 56% of the way up
2.946.53

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Robert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Employees1460
IPONov 09, 2020
Beta0.23
ATR, 14d0.26
Rel volume0.52
Short float3.56%
Insider own55.53%
Inst own11.14%

Snapshot

6 groups

Valuation

Index-
Market Cap1.93B
Enterprise Value3.24B
Income-179.59M
Sales491.95M
Book/sh-0.54
Cash/sh0.37
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees1460
IPONov 09, 2020

Ratios

P/E-
Forward P/E21.25
PEG-
P/S3.92
P/B-
P/C13.52
P/FCF-
EV/EBITDA37.59
EV/Sales6.59
Quick Ratio0.96
Current Ratio1.65
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.56
EPS next Y0.23
EPS next Q-0.04
EPS this Y89.20%
EPS next Y2254.98%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y91.85% -
EPS Y/Y TTM-365.51%
Sales Y/Y TTM-12.17%
EPS Q/Q-276.37%
Sales Q/Q-38.94%
EarningsNov 11 AMC
EPS/Sales Surpr.-62.17% 2.91%

Ownership

Insider Own55.53%
Insider Trans0.00%
Inst Own11.14%
Inst Trans8.21%
ROA-12.05%
ROE-
ROIC-14.88%
Gross Margin60.45%
Oper. Margin9.12%
Profit Margin-36.51%
SMA202.57%
SMA50-6.16%
SMA20017.95%
Trades-

Technical

Shs Outstand356.82M
Shs Float173.61M
Short Float3.56%
Short Ratio5.79
Short Interest6.18M
52W High6.53 -24.27%
52W Low2.94 68.20%
Volatility5.84% 5.19%
ATR (14)0.26
RSI (14)50.00
Beta0.23
Rel Volume0.52
Avg Volume1.07M
Volume69,221

Performance

Perf Week5.89%
Perf Month-8.09%
Perf Quarter20.90%
Perf Half Y34.74%
Perf YTD-3.61%
Perf Year-11.38%
Perf 3Y-45.12%
Perf 5Y-50.05%
Perf 10Y-
Recom1.33
Target Price7.59
Prev Close4.88
Price4.95
Change %1.33%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Nov 10, 2026InitiatedJJefferiesBuy$9+82.0%
Sep 16, 2026UpgradeBBarclaysUnderweight → Overweight$8+61.8%
Aug 24, 2026InitiatedBBofA SecuritiesBuy$7+41.6%
Aug 14, 2026InitiatedEEvercore ISIOutperform
Dec 09, 2025InitiatedBBarclaysUnderweight$5+1.1%
Nov 04, 2025DowngradeDDeutsche BankBuy → Hold$8+61.8%
Oct 14, 2025UpgradeMMorgan StanleyEqual-Weight → Overweight$14+183.1%
Sep 23, 2025UpgradeDDeutsche BankHold → Buy$14+183.1%
Feb 14, 2025InitiatedUUBSBuy$18+264.0%
Jan 29, 2024UpgradeBBarclaysEqual Weight → Overweight$10 → $17+243.8%

Peers

Mkt cap
TickerCompanyMkt cap
TEVATeva- Pharmaceutical Industries Ltd49.60B
AMRXAmneal Pharmaceuticals Inc7.55B
OGNOrganon & Co3.64B
RDYDr. Reddy's Laboratories Ltd ADR12.27B
EVOEvotec SE ADR589.60M
VTRSViatris Inc23.84B
AMPHAmphastar Pharmaceuticals Inc1.23B
ANIPANI Pharmaceuticals Inc1.63B
AMGNAMGEN Inc250.04B
PFEPfizer Inc166.46B

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
IDNAiShares Genomics Immunology and Healthcare ETFAUM: 354.14M
EWXState Street SPDR S&P Emerging Markets Small Cap ETFAUM: 617.94M
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
GLCRGlacierShares Nasdaq Iceland ETFAUM: 1.42M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M
KBFRInnovator U.S. Small Cap Managed 10 Buffer ETFAUM: 13.50M

News

latest 14 of 206
  • Alvotech Must Show Its Factory Is Back To Speed Before A Heavy Fourth Quarter (Earnings Whispers)
  • Alvotech to Present at Upcoming Investor Conferences in November (GlobeNewswire)
  • Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026 (GlobeNewswire)
  • Alvotech shares jump premarket after FDA approves new Simlandi process (Investing.com)
  • Alvotech Receives FDA Approval for New SIMLANDI Manufacturing Process That More Than Doubles Output Per Batch (GlobeNewswire)
  • Loading…
  • Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea 8 mg (GlobeNewswire)
  • Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply (GlobeNewswire)
  • Alvotech Soars 13% on FDA Nod That Effectively Doubles US Humira Biosimilar Capacity (TIKR) +12.11%
  • Alvotech stock surges after FDA manufacturing approval (Investing.com)
  • FDA approves additional U.S. manufacturing capacity for SIMLANDI, Alvotech's biosimilar to Humira (GlobeNewswire)
  • ALVO Stock Jumps On Double Upgrade Why Barclays Sees A 59% Upside (Stocktwits)
  • Alvotech Shares Rise 5.6% After Barclays Upgrades Rating and Doubles Price Target (InvestorsHub)
  • Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio to Subcutaneous Presentations (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-11--0.037--125.27
2026Q22026-08-19-0.085-0.053-0.1941061035
2026Q12026-05-06-0.090-0.0470.003105.9112.394
2025Q42026-03-180.008-0.006-0.356173.2162.194
2025Q32025-11-12-0.087-0.027-0.017113.98116.324
2025Q22025-08-130.030-0.0460.106173.23117.342
2025Q12025-05-070.350-0.1130.363132.895.021
2024Q42025-03-26-0.167-0.027-0.222152.7997.991
2024Q32024-11-13-0.029-0.063-0.03810385.001
2024Q22024-08-150.0130.0030.233198.8-1
2024Q12024-05-21-0.890-0.083-0.82037.00-1
2023Q42024-03-20-0.8000.042-1.03754.1593.002
2023Q32023-11-28-0.580-0.070-0.70518.00-1
2023Q22023-08-30-0.060-0.1400.7194.0042.001
2023Q12023-05-19-1.240--1.05215.86--
2022Q32022-11-150.020--0.03519.00--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-12.290-0.12836.80-
2022FY-1.780-1.145-2.59884.50108.84
2023FY-2.430-1.105-2.42893.4086.00
2024FY-0.870-0.126-0.865492454.43
2025FY-0.100-0.0810.540593.2581.24
2026FY--0.011--598.9
2027FY-0.233--742.7
2028FY-0.456--916.37
2029FY-0.863--1,158
2030FY-1.268--1,318

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-09602125.294.00149
2026Q3S2026-11-06401126.0394.00149
2026Q3S2026-11-05502125.8294.00149
2026Q3S2026-11-04501134.2294.00167
2026Q3S2026-10-16511134.2294.00167
2026Q3S2026-10-12511139.2294.00167
2026Q3S2026-10-09521139.2294.00167
2026Q3S2026-08-24421136.7894.00167
2026Q3S2026-08-21321151.04123167
2026Q3S2026-08-20220184.05167201.11
2026Q3S2026-08-19220184.05167201.11
2026Q3S2026-08-15220184.05167201.11
2026Q3S2026-07-29320158.37107201.11
2026Q3S2026-07-14310156.37107201.11

Estimate history

EPS, annual-0.2970.128-2.598-2.428-0.8650.096-0.5573
Period202020212022202320242025TTM
EPS, quarterly0.233-0.038-0.2220.3630.106-0.017-0.3560.003-0.187
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0083.02991.434489.682586.321491.95
Period202020212022202320242025TTM
Sales, quarterly198.738102.887151.205132.765173.239113.744166.573105.865105.772
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual31.2531.25248.65266.822301.806312.021356.817
Period202020212022202320242025MRQ
Shares, quarterly279.408301.482301.806301.806301.806301.806312.021330.284356.817
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue491.95586.32489.6891.4383.030.000.00
Cost of Goods Sold Incl. D&A194.57251.44197.93169.4874.450.000.00
Gross Profit297.38334.88291.75-78.058.580.000.00
Selling, General and Administrative Excl. Other252.50259.26224.41276.98354.255.860.27
Research and Development137.67174.34162.95203.94170.87--
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income44.8875.6267.35-355.03-345.68-5.86-0.27
Interest Expense158.83146.08157.60134.8291.44-0.43
Unusual Expense0.00-192.62139.41155.63128.00-9.858.57
Net Income Before Taxes-32.16136.35-217.56-643.90-551.653.99-9.27
Income Taxes147.43108.4314.30-99.32-38.070.000.00
Consolidated Net Income-179.5927.92-231.86-551.73-513.583.99-9.27
Net Income From Continuing Operations-179.5927.92-231.86-551.73-513.583.99-9.27
Net Income-179.5927.92-231.86-551.73-513.583.99-9.27
EPS (Recurring)-0.50-0.37-0.50-1.95-2.14-0.09-0.10
EPS (Basic, Before Extraordinaries)-0.560.10-0.87-2.43-2.600.13-0.30
EPS (Diluted)-0.560.10-0.87-2.43-2.600.13-0.30
EBITDA86.19113.4798.65-330.82-325.27-5.86-0.27
Non-Operating Income (Expense)81.7914.1912.101.5913.470.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense7.025.625.7212.867.74--
Price To Earnings Ratio----1,492.541,492.54-
Price To Sales Ratio2.682.557.2428.5323.81--
Gross Margin60.4557.1259.58-85.3610.33--
Operating Margin9.1212.9013.75-388.29-416.33--
Net Margin-36.514.76-47.35-603.42-618.55--
Shares Outstanding356.82312.02301.81266.82248.6531.2531.25
Market Capitalization1,905.311,905.313,988.613,068.022,486.492,486.49-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue105.77105.86166.57113.74173.24132.76151.21102.89
Cost of Goods Sold Incl. D&A52.2046.0961.2835.0173.8365.4580.3339.81
Gross Profit53.5859.78105.2978.7499.4167.3270.8863.08
Selling, General and Administrative Excl. Other65.4150.1859.3677.5481.4656.7859.5450.45
Research and Development21.8624.5139.6951.6254.7238.1740.2633.57
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-11.849.5945.931.2017.9510.5411.3412.62
Interest Expense41.0240.8140.7436.2636.6535.5465.48-
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-66.760.9939.70-6.099.3193.42-44.44-24.75
Income Taxes0.06-0.04148.25-0.83-22.73-16.2622.53-13.36
Consolidated Net Income-66.821.03-108.55-5.2532.04109.68-66.97-11.39
Net Income From Continuing Operations-66.821.03-108.55-5.2532.04109.68-66.97-11.39
Net Income-66.821.03-108.55-5.2532.04109.68-66.97-11.39
EPS (Recurring)-0.190.00-0.36-0.020.110.36-0.22-0.04
EPS (Basic, Before Extraordinaries)-0.190.00-0.36-0.020.110.36-0.22-0.04
EPS (Diluted)-0.190.00-0.36-0.020.110.36-0.22-0.04
EBITDA-1.5119.8856.3511.4826.8518.8019.4921.02
Non-Operating Income (Expense)-13.9032.2034.5128.9828.01118.429.71-37.37
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.221.780.922.091.611.00-1.94
Price To Earnings Ratio-35.5822.2839.0227.05---
Price To Sales Ratio2.682.032.674.334.914.988.589.76
Gross Margin50.6556.4763.2169.2257.3950.7046.8761.31
Operating Margin-11.199.0627.581.0510.367.947.5012.27
Net Margin-63.170.97-65.16-4.6218.4982.61-44.29-11.07
Shares Outstanding356.82330.28312.02301.81301.81301.81301.81301.48
Market Capitalization1,905.311,132.871,497.962,471.792,752.472,915.333,988.613,587.64

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments172.3651.4311.1666.430.591.28
Short Term Receivables153.79251.7287.2271.390.000.00
Inventories220.05127.8974.4371.470.000.00
Other Current Assets27.8223.9822.0421.450.100.25
Total Current Assets574.01455.02194.84230.740.691.53
Net Property, Plant & Equipment494.69409.74356.58268.100.000.00
Total Investments and Advances0.000.0044.6373.75250.03250.01
Long-Term Note Receivable122.9322.7110.863.29--
Intangible Assets94.6731.9531.1337.300.000.00
Deferred Tax Assets192.21298.36309.81209.50--
Other Assets8.583.622.245.780.000.00
Total Assets1,487.101,221.40950.09828.44250.72251.53
Short Term Debt Incl. Current Port. of LT Debt49.0042.2247.7125.080.120.12
Accounts Payable126.1267.1380.5649.190.000.00
Income Tax Payable1.040.200.930.93--
Other Current Liabilities127.9183.85131.7592.095.260.26
Total Current Liabilities304.08193.40260.95167.295.380.38
Long Term Debt1,400.151,148.021,027.77780.020.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities7.871.810.050.31--
Other Liabilities59.49290.94593.81445.2320.4230.22
Total Liabilities1,771.591,634.171,882.581,392.8625.8030.61
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-284.49-412.77-932.49-564.42224.92220.93
Total Shareholders Equity-284.49-412.77-932.49-564.42224.92220.93
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-284.49-412.77-932.49-564.42224.92220.93
Total Liabilities & Stockholders Equity1,487.101,221.40950.09828.44250.72251.53
Book Value Per Share-0.91-1.37-3.49-2.277.207.07
Tangible Book Value Per Share-1.22-1.47-3.61-2.427.207.07
Full-Time Employees1,4601,0321,02694744
Price to Book Ratio-9.09-11.60-4.641.391.39-
Return on Assets2.06-21.36-62.04-95.181.59-
Return on Equity----1.79-
Return on Invested Capital2.50-31.54-579.11-238.201.78-4.20
Quick Ratio1.161.690.460.950.134.00
Current Ratio1.892.350.751.380.134.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-179.5927.92-231.86-551.73-513.583.99-9.27
Depreciation41.3137.8531.3024.2120.41--
Other Funds (Non Cash)28.76-104.93239.16289.57228.67-9.859.03
Funds from Operations-2.9267.4451.80-338.51-264.50-5.86-0.24
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-195.78-117.64-288.6426.33-47.895.23-0.13
Cash from Operating Activities-198.70-50.20-236.84-312.19-312.39-0.63-0.37
Capital Expenditures-135.12-96.13-57.00-46.47-49.000.000.00
Net Assets From Acquisitions-14.04-14.040.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.130.380.000.00
Purchase or Sale of Investments2.985.9512.000.000.000.03-250.00
Purchase of Investments0.000.000.000.000.000.00-250.00
Sale Or Maturity of Investments2.985.9512.000.000.000.030.00
Other Uses0.000.000.000.00-14.910.000.00
Other Sources-0.0026.130.00-0.000.00
Cash from Investing Activities-146.18-104.22-18.87-46.34-63.540.03-250.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock156.0878.72149.56139.13-9.80-0.09251.59
Repurchase of Common Pref Stock0.000.000.00-4.14-9.800.000.00
Sale of Common Pref Stock156.0878.72149.56143.270.00-0.09251.59
Proceedsfrom Stock Options156.0878.72144.64136.880.00-0.09251.59
Issuance or Reduction of Debt, Net-202.48157.94170.46245.720.000.06
Change in Long Term Debt----245.720.000.00
Issuance of Long Term Debt----353.680.000.00
Reduction of Long Term Debt-----107.960.000.00
Net Financing Active Other Cash Flow0.000.000.000.00189.000.000.00
Other Financing Activities Uses0.000.000.000.00-5.560.000.00
Cash from Financing Activities335.93270.83297.31301.32424.91-0.09251.65
Exchange Rate Effect0.254.51-1.321.94-0.11--
Net Change in Cash-8.70120.9340.27-55.2748.87-0.691.28
Free Cash Flow-261.38-114.67-290.50-345.42-350.27-0.63-0.37
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-106.6013.20-100.560.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments142.7563.83172.3642.85151.4538.54
Short Term Receivables115.43106.87153.79122.35154.94228.75
Inventories226.55228.02220.05207.73155.49142.07
Other Current Assets60.2357.2627.8259.0847.5849.50
Total Current Assets544.97455.98574.01432.01509.46458.87
Net Property, Plant & Equipment515.29495.23494.69494.18441.08422.91
Total Investments and Advances0.000.000.004.390.000.00
Intangible Assets154.94132.1194.6774.6767.4832.62
Deferred Tax Assets192.84192.86192.21340.50338.33315.35
Other Assets14.4214.968.584.734.343.55
Total Assets1,587.471,421.171,487.101,409.181,392.751,245.46
Short Term Debt Incl. Current Port. of LT Debt53.7755.6449.0056.0259.6243.82
Accounts Payable133.1697.86126.1291.6384.2867.89
Income Tax Payable2.002.051.041.770.740.67
Other Current Liabilities142.24104.23127.91154.65135.11153.44
Total Current Liabilities331.18259.78304.08304.07279.75265.81
Long Term Debt1,398.011,401.641,400.151,226.141,208.401,183.13
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities6.907.167.877.542.012.06
Other Liabilities42.8634.8959.4948.1975.9296.75
Total Liabilities1,778.951,703.481,771.591,585.941,566.081,547.75
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-191.48-282.31-284.49-176.76-173.33-302.29
Total Shareholders Equity-191.48-282.31-284.49-176.76-173.33-302.29
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-191.48-282.31-284.49-176.76-173.33-302.29
Total Liabilities & Stockholders Equity1,587.471,421.171,487.101,409.181,392.751,245.46
Book Value Per Share-0.54-0.85-0.91-0.59-0.57-1.00
Tangible Book Value Per Share-0.97-1.25-1.22-0.83-0.80-1.11
Full-Time Employees--1,460---
Price to Book Ratio-9.09-3.76-8.76-14.26-9.11-7.07
Return on Assets-12.05-6.052.065.265.158.37
Return on Invested Capital-5.540.09-9.73-0.503.1012.45
Quick Ratio0.960.881.160.741.271.19
Current Ratio1.651.761.891.421.821.73

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-66.821.03-108.55-5.2532.04109.68
Depreciation10.3310.2910.4110.288.908.26
Other Funds (Non Cash)42.87-21.148.50-1.47-10.02-101.94
Funds from Operations-13.62-9.8216.973.5630.9216.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-6.16-50.61-79.88-59.1324.82-3.45
Cash from Operating Activities-19.79-60.43-62.91-55.5855.7412.55
Capital Expenditures-44.77-46.20-15.77-28.39-28.60-23.37
Net Assets From Acquisitions0.000.000.00-14.040.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.002.980.002.98
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.002.980.002.98
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.00---
Cash from Investing Activities-44.77-46.20-15.77-39.45-28.60-20.39
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock156.080.000.000.0078.720.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock156.080.000.000.0078.720.00
Proceedsfrom Stock Options156.080.000.000.0078.720.00
Issuance or Reduction of Debt, Net-9.632.20208.85-9.887.07-3.56
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities143.38-0.97206.77-13.2483.15-5.84
Exchange Rate Effect0.10-0.941.42-0.332.620.80
Net Change in Cash78.92-108.53129.51-108.60112.91-12.88
Free Cash Flow-47.65-67.57-71.65-74.5042.12-10.64

Revenue breakdown

Development And Other Service2024: 98.01M 2025: 150.11M
License revenue2024: 75.81M 2025: 110.98M
Performance2024: 42.39M 2025: 48.96M
Product revenue2024: 273.47M 2025: 276.27M
Europe2024: 157.59M 2025: 307.22M
Rest Of The World2024: 59.06M 2025: 37.73M
United States2024: 273.04M 2025: 241.37M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.56%6.2M173.6M1.06M
2026-10-153.67%6.4M173.6M1.07M
2026-09-303.66%6.4M173.6M984.17K
2026-09-153.35%5.8M173.6M933.81K
2026-08-313.22%5.6M173.6M991.53K
2026-08-142.97%5.2M173.6M850.57K
2026-07-313.29%4.6M140.1M802.79K
2026-07-152.81%3.9M140.1M707.12K
2026-06-302.83%2.9M103.2M670.83K
2026-06-153.02%3.7M120.9M567.52K
2026-05-292.60%2.9M112.7M505.56K
2026-05-152.25%2.5M112.7M555.48K
2026-04-301.92%2.4M123.7M548.17K
2026-04-152.52%2.7M107.0M531.17K
2026-03-312.80%3.0M107.0M543.89K
2026-03-132.17%2.5M113.3M524.88K
2026-02-272.89%3.0M102.5M515.34K
2026-02-132.44%2.5M102.5M470.10K
2026-01-302.50%2.4M97.9M601.84K
2026-01-152.34%2.3M97.9M603.78K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-20SEC
2026-10-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-14SEC
2026-10-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-06SEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-05SEC
2026-08-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-31SEC
2026-08-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-21SEC
2026-08-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-29SEC
2026-07-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-01SEC
2026-06-30SCHEDULE 13D/ASEC
2026-06-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-18SEC
2026-06-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-16SEC
2026-06-16424B5SEC
2026-06-16FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-06-15FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-06-15424B5SEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-15SEC
2026-06-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-06-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-04SEC
2026-05-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-11SEC
2026-05-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-30SEC
2026-03-3120-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-31SEC
2026-03-12SCHEDULE 13D/ASEC
2026-02-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-27SEC
2026-02-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-05SEC
2026-02-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-02SEC
2026-01-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-29SEC
2026-01-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-07SEC
2026-01-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Rubric Capital Management LP4.64%
MILLENNIUM MANAGEMENT LLC1.26%
Bracebridge Capital, LLC1.19%
VANGUARD CAPITAL MANAGEMENT LLC1.09%
FARALLON CAPITAL MANAGEMENT, L.L.C.0.85%
CITADEL ADVISORS LLC0.51%
PRICE T ROWE ASSOCIATES INC /MD/0.42%
BlackRock, Inc.0.39%
LITTLEJOHN & CO LLC0.34%
VANGUARD FIDUCIARY TRUST CO0.30%

Funds

Fund% owned
T. Rowe Price International Discovery Fund0.29%
iShares Biotechnology ETF0.25%
Royce Smaller-Companies Growth Fund0.15%
Global Macro Absolute Return Advantage Portfolio0.15%
Global Macro Portfolio0.04%
Schwab Emerging Markets Equity ETF0.03%
Fidelity Nasdaq Composite Index ETF0.03%
Fidelity Nasdaq Composite Index Fund0.03%
Invesco RAFI US 1500 Small-Mid ETF0.02%
Parametric Emerging Markets Fund0.02%

OakChart. ALVO. Cached 15 minutes.

Some panels did not load: insider.